Key Details
Price
$16.50Last Dividend
$1.00Annual Revenue
$159.01 MAnnual EPS
-$0.51Annual ROE
-22.08%Beta
1.48Events Calendar
Next earnings date:
Mar 05, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Mar 05, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Jan 27, 2010Next split:
N/ARecent split:
July 11, 1994Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The mean of analysts' price targets for AxoGen (AXGN) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Axogen, Inc (NASDAQ:AXGN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning, everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer.
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Bioventus, Great Lakes Dredge & Dock, and AxoGen have been selected as the breakout stocks for today.
ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®.
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen (AXGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.03 per share a year ago.
FAQ
- What is the primary business of AxoGen?
- What is the ticker symbol for AxoGen?
- Does AxoGen pay dividends?
- What sector is AxoGen in?
- What industry is AxoGen in?
- What country is AxoGen based in?
- When did AxoGen go public?
- Is AxoGen in the S&P 500?
- Is AxoGen in the NASDAQ 100?
- Is AxoGen in the Dow Jones?
- When was AxoGen's last earnings report?
- When does AxoGen report earnings?
- Should I buy AxoGen stock now?